What next for the pharmaceutical industry?

Among other changes implied by the UK government’s NHS reforms, prescribing will be more tightly controlled than ever; responsibility for public health will increasingly be with local government; and commissioning consortia will further alter the stakeholder landscape. The pharma industry needs to get ready by adjusting its commercial model.

Mike Sobanja, Chief Executive, NHS Alliance, shares his views with Capgemini’s Mark Holliday.